SCHEMBL396930

SCHEMBL396930

Cc1c(Br)c([N+](=O)[O-])cc(OC(=O)O)c1C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
ALDH1A1 P00352 7/20 0.36
TSHR P16473 4/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HTT P42858 2/20 0.33
GPR35 Q9HC97 2/20 0.33
HPGD P15428 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NPC1 O15118 2/20 0.32
MAPK1 P28482 2/20 0.32
RAB9A P51151 2/20 0.32
GLA P06280 1/20 0.32
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396928 1.00 CYP1A2 (0.39) CYP1A2ALDH1A1TSHRTDP1MAPT
SCHEMBL3983714 0.75 ALDH1A1 (0.38) ALDH1A1TSHRTDP1MAPTMEN1
SCHEMBL3983716 0.75 ALDH1A1 (0.38) ALDH1A1TSHRTDP1MAPTMEN1
SCHEMBL17030192 0.75 ALDH1A1 (0.38) ALDH1A1TSHRTDP1MAPTMEN1
SCHEMBL29551672 0.73 ALDH1A1 (0.40) ALDH1A1TSHRTDP1MAPTMEN1
SCHEMBL399301 0.69 PTGDR2 (0.35) CYP1A2ALDH1A1HPGD
SCHEMBL29197552 0.68 CYP1A2 (0.49) CYP1A2ALDH1A1TSHRTDP1MAPT
SCHEMBL29038591 0.67 GPR35 (0.55) CYP1A2ALDH1A1TSHRTDP1MAPT
SCHEMBL9444985 0.67 TDP1 (0.39) ALDH1A1TDP1MAPTMEN1KMT2A
SCHEMBL9444978 0.67 TDP1 (0.39) ALDH1A1TDP1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150315186-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2015-11-05 US disclosed
US-8101767-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-24 US disclosed
US-20110098311-A1 COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES Vertex Pharmaceuticals Incorported (US) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098311-A1 COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES CFTR, SLC26A4, ABCB11 CYP1A2 1677/4885ALDH1A1 2535/4885TSHR 3893/4885
US-20150315186-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 CYP1A2 2537/4885ALDH1A1 2165/4885TSHR 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.